E3 ligase Ligand-Linker Conjugates 8 (Synonyms: VH032-C6-PEG3-C4-Cl; VHL Ligand-Linker Conjugates 12; E3 ligase Ligand-Linker Conjugates 8) |
| Katalog-Nr.GC32987 |
E3-Ligase-Ligand-Linker-Konjugate 8 (VH032-C6-PEG3-C4-Cl) ist ein Konjugat aus Liganden fÜr E3 und einem Linker mit einer LÄnge von 20 Atomen. Der Verbinder des Linkers ist eine Halogengruppe. E3-Ligase-Ligand-Linker-Konjugate 8 enthalten den (S,R,S)-AHPC-basierten VHL-Liganden und einen Alkyl/Ether-basierten Linker. E3-Ligase-Ligand-Linker-Konjugate 8 kÖnnen den Abbau von GFP-HaloTag7 in zellbasierten Assays induzieren.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1835705-55-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
E3 ligase Ligand-Linker Conjugates 8 is a synthesized compound that incorporates an E3 ligase ligand and a linker used in PROTAC technology.
E3 ligase Ligand-Linker Conjugates 8 uses the cereblon ligand[1]. The linker is 6-2-2-6. The linkers contain a mixture of hydrophobic and hydrophilic moieties to balance the hydrophobicity/hydrophilicity of the resulting hybrid compounds. PROTACs that induce the degradation of an oncogenic tyrosine kinase, BCR-ABL has been developed. E3 ligase Ligand-Linker Conjugates 8 can be attached to potent TKIs (bosutinib and dasatinib) that mediate the degradation of c-ABL and BCR-ABL by hijacking either CRBN or VHL E3 ubiquitin ligase [2].
[1]. US 20170121321 A1 [2]. Lai AC, et al. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10.
Average Rating: 5 (Based on Reviews and 8 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *